Company: ANTX
Filing Date: 2025-03-25
Form Type: 10-K
Source: 0000950170-25-044366
Chunk: 40

Company: AN2 Therapeutics, Inc.
Filing Date: 2025-03-25
Form: 10-K
Item: Item 16
Chunk 40
---
2022

    10.9#
     
    Form of Indemnity Agreement by and between the Registrant and its directors and executive officers.
     
    S-1
     
    333-263295
     
    10.9
     
    March 4, 2022

    10.10#
     
    Offer Letter by and between the Registrant and Eric Easom, dated November 19, 2019.
     
    S-1
     
    333-263295
     
    10.10
     
    March 4, 2022

    10.11#
     
    Offer Letter by and between the Registrant and Lucy Day, dated November 19, 2019.
     
    S-1
     
    333-263295
     
    10.11
     
    March 4, 2022

    10.12#
     
    Offer Letter by and between the Registrant and Sanjay Chanda, dated November 19, 2019.
     
    S-1
     
    333-263295
     
    10.12
     
    March 4, 2022

    10.13‡
     
    License Agreement by and between the Registrant and Anacor Pharmaceuticals, Inc., dated November 20, 2019, as amended on December 3, 2021.
     
    S-1
     
    333-263295
     
    10.13
     
    March 4, 2022

    10.14‡
     
    License Agreement by and between the Registrant and Brii Biosciences Limited, dated November 20, 2019.
     
    S-1
     
    333-263295
     
    10.14
     
    March 4, 2022

    10.15
     
    Amended and Restated Global Health Agreement by and among the Registrant, Adjuvant Global Health Technology Fund L.P., and Adjuvant Global Health Technology Fund DE L.P., dated March 5, 2021.
     
    S-1
     
    333-263295
     
    10.15
     
    March 4, 2022

91